Search results
Results from the WOW.Com Content Network
More than 1,200 men were promised a clean bed, three free square meals a day and free medical care if they were found to have prostate cancer. Hudson's early experience with seeing patients dying at a tuberculosis hospital he was working at led him to develop an interest in prostate cancer. His discovery about the lack of information regarding ...
Its extract has been promoted as a prostate cancer medicine; however, according to the American Cancer Society, "available scientific studies do not support claims that saw palmetto can prevent or treat prostate cancer in humans". [100] Seasilver – an expensive dietary supplement made mostly from plant extracts and promoted by two U.S. companies.
New research links omega-6 fatty acids, commonly found in seed oils, and colon cancer growth. But there’s more to the story—and study if you read it carefully.
[90] One study has found a positive connection between trans fat and prostate cancer. [91] However, a larger study found a correlation between trans fats and a significant decrease in high-grade prostate cancer. [92] An increased intake of trans fatty acids may raise the risk of breast cancer by 75%, suggest the results from the French part of ...
Doctors are hoping the “olive oil drug” 2-OHOA can treat a deadly and incurable brain cancer, since the results of an early trial show promise for glioblastoma patients. ardanz – stock.adobe.com
Diethylstilbestrol (DES), also known as stilbestrol or stilboestrol, is a nonsteroidal estrogen medication, which is presently rarely used. [5] [6] [7] In the past, it was widely used for a variety of indications, including pregnancy support for those with a history of recurrent miscarriage, hormone therapy for menopausal symptoms and estrogen deficiency, treatment of prostate cancer and ...
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
One 2021 study from JAMA Oncology aimed to compare the effectiveness and safety determined in randomized clinical trials of systemic treatments for metastatic castration-sensitive prostate cancer (mCSPC). The study found that "as add-on treatments to ADT, abiraterone acetate and apalutamide may provide the largest overall survival benefits with ...